BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses.
BioMarin Pharmaceutical Inc. will receive royalties equal to 20% of U.S. Yuviwel net sales, retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea through May 2030. The settlement resolves proceedings before the U.S. International Trade Commission and courts in several countries. The financial question is whether those royalties can offset the competitive pressure on Voxzogo.
Bull Case
The agreement eliminates litigation costs and uncertainty over excluding Yuviwel from major markets. BioMarin Pharmaceutical Inc. instead gains royalties without funding Yuviwel’s manufacturing, commercialization, or clinical development. That income should carry lower incremental costs than product sales.
Yuviwel remains early in its launch. Ascendis Pharma A/S reported €8 million of second-quarter 2026 Yuviwel revenue and more than 220 unique U.S. patient enrollments through July 31, with over 65% approved for reimbursement. Payments to BioMarin Pharmaceutical Inc. remain limited but will rise if Yuviwel net sales increase.
The license extends beyond Yuviwel’s current achondroplasia indication. It covers patents held by BioMarin Pharmaceutical Inc. relating to all current and potential Yuviwel indications, including hypochondroplasia, and Yuviwel combinations with other medicines. BioMarin Pharmaceutical Inc. will participate in some economic upside if Ascendis Pharma A/S expands the franchise.
The retroactive U.S. provision is another benefit. BioMarin Pharmaceutical Inc. will receive royalties from Yuviwel’s first commercial sale rather than only from the settlement date.
Bear Case
Royalties do not eliminate cannibalization. BioMarin Pharmaceutical Inc. expects Voxzogo revenue of $1.0 billion to $1.05 billion in 2026, making the daily injection a major franchise. Yuviwel’s once-weekly dosing could attract patients who otherwise would have used Voxzogo.
If one dollar of Yuviwel sales directly replaces one dollar of Voxzogo sales, a 20% royalty recovers only part of the displaced revenue. The economic effect will depend on product margins, pricing, market expansion, and how likely BioMarin Pharmaceutical Inc. was to prevail in the litigation. The settlement is more attractive if Yuviwel brings additional patients into treatment rather than primarily taking market share.
The broad license also reduces future blocking leverage. Hypochondroplasia and combination therapy could become important extensions, yet patents held by BioMarin Pharmaceutical Inc. relating to those potential Yuviwel uses are now licensed through the settlement. The royalties apply for a relatively short period ending in May 2030 and cover only specified international markets outside the United States.
Yuviwel also received accelerated U.S. approval based on improved annualized growth velocity. Continued approval may depend on confirmatory evidence of clinical benefit. Weak adoption would limit royalty income, while strong adoption could intensify competition with Voxzogo.
Hedge Fund Sentiment
The filings available so far reflect positions held before BioMarin Pharmaceutical Inc. announced the global Yuviwel patent settlement. Insider Monkey’s database showed 54 hedge funds holding BioMarin Pharmaceutical Inc. at the end of 2Q2026, down from 62 funds three months earlier.
Conclusion
Monetization is financially rational because it removes legal costs and captures part of Yuviwel’s future economics. However, the royalty is a partial hedge rather than a complete answer to competition. The agreement creates clear value if Yuviwel expands the treated population or succeeds in additional indications. If Yuviwel mainly displaces Voxzogo, BioMarin Pharmaceutical Inc. will receive royalties while surrendering potentially higher-value product economics. The outcome therefore depends on whether market expansion outweighs franchise cannibalization through May 2030.
READ NEXT: Main Street Capital’s (MAIN) Blowout Exit Fuels A Bigger Dividend and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
This article is originally published at Insider Monkey.
Hedge Fund Resource Center